TABLE 2.
Summary of results obtained for MRSE isolates from Denmark
| PFGE type; no. (%) of isolatesa | PFGE subtype (no. of isolates) | Antibiotype (>50%)b,c | Clinical data
|
||
|---|---|---|---|---|---|
| Hospital(s)d | Source(s)e | Infection or colonizatione | |||
| A; 25 (18.4) | A1 (8) | CIP, GEN, OXA, SXT | AH, B, C, HV | Bl, W, ot | I, C |
| A2 (5) | |||||
| A3 (3) | |||||
| A4 (2) | |||||
| A5 (2) | |||||
| A6 (1) | |||||
| A7 (1) | |||||
| A8 (1) | |||||
| A9 (1) | |||||
| A10 (1) | |||||
| B; 16 (11.8) | B1 (15) | CIP, GEN, OXA, SXT | AH, B, C, D, HV | Bl, A, W, ot | I, C |
| B2 (1) | |||||
| C; 16 (11.8) | C1 (1) | ERY, GEN, OXA, SXT | AH, B, C, D, HV | Bl, A, W, ot | I, C |
| C2 (5) | |||||
| C3 (3) | |||||
| C4 (2) | |||||
| C5 (1) | |||||
| C6 (1) | |||||
| C7 (1) | |||||
| C12 (2) | |||||
| K; 15 (11.0) | K1 (12) | ERY, GEN, OXA | AH, B, C, D, HV | BI, R, W, A, ot | I, C |
| K2 (3) | |||||
| D; 10 (7.4) | D1 (6) | CHL, ERY, GEN, OXA, SXT | C, HV | Bl, R, ot | I, C |
| D2 (3) | |||||
| D3 (1) | |||||
| F; 9 (6.6) | F1 (3) | GEN, OXA | AH, C, D, HV | Bl, ot | I, C |
| F2 (1) | |||||
| F3 (1) | |||||
| F4 (1) | |||||
| F5 (1) | |||||
| F6 (1) | |||||
| F7 (1) | |||||
| G; 5 (3.7) | G1 (2) | CIP, CLI, ERY, GEN, OXA, SXT | B, C, HV | Bl, R, W, ot | I, C |
| G2 (1) | |||||
| G3 (2) | |||||
| H; 5 (3.7) | H1 (3) | GEN, RIF, OXA, SXT | AH, C, HV | Bl, R, ot | C |
| H2 (1) | |||||
| H4 (1) | |||||
| I; 4 (2.9) | I1 (1) | ERY, GEN, OXA, TET | C, HV | Bl, W | C |
| I2 (2) | |||||
| I3 (1) | |||||
| J; 4 (2.9) | J1 (3) | ERY, OXA | C, D, HV | Bl | C |
| J2 (1) | |||||
| E; 3 (2.2) | E1 (2) | CHL, GEN, OXA, RIF, TET | AH, B, C | Bl | I, C |
| E2 (1) | |||||
| L; 3 (2.2) | L1 (3) | GEN, OXA | C, HV | Bl, W | C |
| Q; 3 (2.2) | Q1 (2) | ERY, GEN, OXA, SXT | B, C, HV | Bl, ot | I, C |
| Q2 (1) | |||||
| M; 2 (1.5) | M1 (2) | CIP, CLI, ERY, GEN, OXA, RIF, SXT | C, HV | Bl, A | C |
| N; 2 (1.5) | N1 (1) | CLI, ERY, GEN, OXA, SXT | B, HV | Bl, ot | I, C |
| N2 (1) | |||||
| O; 2 (1.5) | O1 (1) | CHL, ERY, GEN, OXA, SXT | B, D | Bl | C |
| O2 (1) | |||||
| P; 2 (1.5) | P1 (1) | ERY, GEN, OXA | HV | Bl | C |
| P2 (1) | |||||
| R; 2 (1.5) | R1 (2) | CIP, CLI, ERY, GEN, OXA, SXT, TET | HV | W | I, C |
| V; 1 (0.7) | V1 (1) | CIP, ERY, GEN, OXA, SXT, TET | AH, HV | Bl | C |
| T; 1 (0.7) | T1 (1) | CHL, ERY, OXA, TET | HV | Bl | C |
| U; 1 (0.7) | U1 (1) | OXA | AH | Bl | |
| W; 1 (0.7) | W1 (1) | OXA | B | Bl | C |
| X; 1 (0.7) | X1 (1) | ERY, GEN, OXA, SXT | C | ot | |
| Z; 1 (0.7) | Z1 (1) | OXA, SXT, TET | AH | Bl | C |
| AA; 1 (0.7) | AA1 (1) | ERY, OXA | HV | Bl | C |
| CC; 1 (0.7) | CC1 (1) | ERY, OXA, TEC | HV | Bl | C |
a
Numbers in parentheses correspond to the frequency of each PFGE type in relation to the total number of MRSE isolates in Denmark.
b
Antibiogram for more than 50% of isolates with this PFGE type.
c
CHL, chloramphenicol; CIP, ciprofloxacin; CLI, clindamycin; ERY, erythromycin; GEN, gentamicin; OXA, oxacillin; RIF, rifampin; TEC, teicoplanin; TET, tetracycline; SXT, trimethoprim-sulfamethoxazole.
d
Hospital codes: AH, Amager hospital (Sundby hospital); B, Herlev hospital; C, Gentofte hospital; D, Glostrup hospital; E, Amager hospital (Sankt Elisabeth hospital); HV, Hvidovre hospital.
e
A, abscess; Bl, blood; C, colonization; I, infection; ot, other sources; R, respiratory tract; W, wound.